Lynch Regenerative Medicine Completes Series A Financing
July 17 2024 - 6:35PM
Business Wire
Company Brings Proven Skin Rejuvenation and
Regeneration Solutions to the Global Skin Care Market
Lynch Regenerative Medicine, LLC (LRM) has completed its Series
A financing to develop and commercialize innovative skin
rejuvenation and regeneration solutions based on the only tissue
growth factor that has been approved by the FDA and other
international regulator bodies to be safe and effective in human
tissue regeneration and wound healing, pure platelet-derived growth
factor (PDGF). LRM’s Series A financing round was led by Champion
VC, a family office investor managing the assets of members of the
Frist family of Nashville, Tennessee, and Dr. Samuel Lynch, founder
and CEO of LRM.
The patented pure PDGF-based technology is currently the main
active component in four FDA-approved products, including two
products for improving healing and regeneration of orthopedic
tissues, and one product each for improving the healing and
regeneration of periodontal tissues and skin. These products have
helped millions of patients around the world over the past 15
years. Now LRM is applying this proven technology to skin
aesthetics.
Dr. Lynch is among the most successful founders and CEOs of
regenerative medicine companies, with LRM being his third company
to introduce pure PDGF-based products to the market. Skincare
represents the largest and fastest-growing market segment for this
technology to date. The market has a need for safe, effective and
proven solutions to rejuvenate and regenerate healthy skin
tissue.
Dr. Lynch, who is recognized worldwide as one of the leading
experts on tissue growth factors, commented, “I’ve spent my career
studying regenerative medicine and developing and commercializing
PDGF products to regenerate tissues lost due to trauma or disease.
I’m most excited to bring pure PDGF-based solutions to the skincare
market, where we see the largest unmet need for proven solutions
for skin rejuvenation and regeneration.”
LRM’s first product to improve skin aesthetics,
Ariessence™ Pure PDGF+ (www.ariessence.com), is
available today and can be found in leading innovative med/spa
clinics and other aesthetic-focused offices, including dermatology
and plastic surgery practices. Ariessence Pure PDGF+ is used
topically to improve aesthetic outcomes associated with procedures
such as micro-needling, dermabrasion, lasers, plastic surgery and
other procedures where the appearance of healthier-looking skin can
be accelerated and enhanced using growth factors such as PDGF.
“Growth factors are playing an important role in skincare today,
but there are no other solutions backed by the level of scientific
and clinical evidence that supports the safety and effectiveness of
pure PDGF,” said Lynch. “Arriessence Pure PDGF+ builds on this
truly unique foundation of success in regenerative medicine.”
LRM will use the capital from the Series A financing to fuel its
commercialization strategy. With the successful closing of this
Series A round, LRM plans to expand its team, bringing in
additional top-tier talent across various disciplines, including
commercialization, business development, clinical development, and
regulatory affairs.
PH Partners acted as financial advisors to LRM, and Bass, Berry
& Sims acted as legal counsel in connection with the
transaction.
Lynch Regenerative Medicine, LLC is pioneering innovative
treatments that aim to revolutionize the $100 billion aesthetics
and wound-care markets. Our mission is to leverage our regenerative
medicine heritage, and our decades-long commitment to safe and
effective regenerative products of the highest quality, to deliver
exceptional results for our customers and their patients and
thereby redefine the future of aesthetic regenerative medicine. The
company was founded in 2023 and is based in Franklin,
Tennessee.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240717195845/en/
Nancy Rocco, n.rocco@lynchregen.com; (888) 576-7343.